These results suggest that chemical inhibition of PARP14 may be a useful strategy for the treatment of ovarian cancer, which is supported by the results of our cell growth and xenograft tumor assays (Fig. 4, B and D; and Fig. S3, A, B, D, and G). This evidence concerns the gene PARP14 and ovarian carcinoma.